Investigating Cancer-related Proteins Specific Domain Interactions and Differential Protein Interactions Caused by Alternative Splicing

A strategy to gain a better understanding of disease proteins is to consider the interactions of these proteins by making use of the protein-protein interaction (PPI) data. It is known that proteins are composed of multiple functional domains. In this article, domain information is introduced to study two biomedical problems. For the first problem, a one to one domain-domain interaction (DDI) model is proposed to obtain specific sets of DDI for onco-proteins and tumor suppressor proteins respectively. Three specific sets of DDI, i.e. oncoprotein and oncoprotein, tumor suppressor protein and tumor suppressor protein, and oncoprotein and tumor suppressor protein, are derived from their PPI. Cross-validation test is conducted to benchmark the prediction sensitivity, specificity and F1 measure. It is found that the oncoprotein and cancer protein DDI set achieved a 74% and 84% F1 measure respectively. This indicates the feasibility of applying DDI model for cancer protein PPI studies, which can contribute to biomedical study Secondly, it is suggested that PPI, which is mediated by DDI, may be affected due to domain removal through the alternative splicing mechanism. Domain removal effects on liver cancer isoforms¡¦ PPI are studied. It is found that certain liver cancer-related isoforms mediated differential PPI. Information are integrated from three pieces of information, i.e. Gene Onotology (GO), gene expression level and PubMed, to provide supporting details for the findings. The Jaccard index is used to rank statistical significant DDI with the above combinations. Finally, web-based platforms have been set up to display the results of the two studied biomedical problems, i.e. http://ppi.bioinfo.asia.edu.tw/TsgOcgppi/ and http://ppi.bioinfo.asia.edu.tw/hccas/search.

[1]  Ozlem Keskin,et al.  Human Cancer Protein-Protein Interaction Network: A Structural Perspective , 2009, PLoS Comput. Biol..

[2]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2008 update , 2008, Nucleic Acids Res..

[3]  R. Sharan,et al.  Protein networks in disease. , 2008, Genome research.

[4]  Russ B Altman,et al.  Large scale study of protein domain distribution in the context of alternative splicing. , 2003, Nucleic acids research.

[5]  Tom M. W. Nye,et al.  Statistical analysis of domains in interacting protein pairs , 2005, Bioinform..

[6]  Cheng-Yan Kao,et al.  Genome-Wide Detection of Putative Oncofetal Genes in Human Hepatocellular Carcinoma by Splicing Pattern Comparison , 2010 .

[7]  L. Holm,et al.  The Pfam protein families database , 2005, Nucleic Acids Res..

[8]  Chia-Hung Liu,et al.  Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online) , 2007, BMC Bioinformatics.

[9]  Pablo Villoslada,et al.  A computational analysis of protein-protein interaction networks in neurodegenerative diseases , 2008, BMC Systems Biology.

[10]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[11]  Arnaud Céol,et al.  3did: identification and classification of domain-based interactions of known three-dimensional structure , 2010, Nucleic Acids Res..

[12]  B. Snel,et al.  Predicting disease genes using protein–protein interactions , 2006, Journal of Medical Genetics.

[13]  Martin Vingron,et al.  Increase of functional diversity by alternative splicing. , 2003, Trends in genetics : TIG.

[14]  Jesús Prieto,et al.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. , 2010, World journal of gastroenterology.

[15]  Narmada Thanki,et al.  CDD: specific functional annotation with the Conserved Domain Database , 2008, Nucleic Acids Res..

[16]  Anne-Mette K. Hein,et al.  Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis*S , 2008, Molecular & Cellular Proteomics.

[17]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[18]  Yongjin Li,et al.  Discovering disease-genes by topological features in human protein-protein interaction network , 2006, Bioinform..

[19]  Arno Lukas,et al.  Characterization of protein-interaction networks in tumors , 2007, BMC Bioinformatics.

[20]  Robert D. Finn,et al.  The Pfam protein families database , 2004, Nucleic Acids Res..

[21]  Borivoj Vojtesek,et al.  p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence , 2009, Nature Cell Biology.

[22]  Dario Cattaneo,et al.  Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. , 2008, European journal of cancer.

[23]  J. Bourdon,et al.  Expression of p53 isoforms in squamous cell carcinoma of the head and neck. , 2007, European journal of cancer.

[24]  Wei Song,et al.  Expression of p53 isoforms in renal cell carcinoma. , 2009, Chinese medical journal.

[25]  J. Yun,et al.  Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas , 2007, Apoptosis.

[26]  Yi Xing,et al.  Assessing the impact of alternative splicing on domain interactions in the human proteome. , 2004, Journal of proteome research.

[27]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[28]  Ker-Chau Li,et al.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.

[29]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[30]  D. Salomon,et al.  Differential expression of epidermal growth factor-related proteins in human colorectal tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Matthews,et al.  Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.

[32]  Ka-Lok Ng,et al.  Prediction of protein functions based on function-function correlation relations , 2010, Comput. Biol. Medicine.

[33]  Ramil N. Nurtdinov,et al.  Alternative splicing and protein function , 2005, BMC Bioinformatics.

[34]  Borivoj Vojtesek,et al.  Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin , 2008, Clinical Cancer Research.

[35]  A. Bateman,et al.  Protein interactions in human genetic diseases , 2008, Genome Biology.

[36]  Yang Sun,et al.  RACK1 promotes Bax oligomerization and dissociates the interaction of Bax and Bcl-XL. , 2010, Cellular signalling.